DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 18564/S-059
NDA 19345/S-044
NDA 18562/S-056
NDA 18563/S-057
NDA 18561/S-057

SUPPLEMENT APPROVAL

Hospira, Inc.
Attention: Mohammed Islaih
Manager, Global Regulatory Affairs
275 North Field Drive
Dept. 0389, Bldg. H2-2
Lake Forest, IL 60045

Dear Mr. Islaih:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received January 6, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA	Supplement	Product Name
18564	S-059	20% Dextrose Injection, USP
19345	S-044	30% Dextrose Injection, USP
18562	S-056	40% Dextrose Injection, USP
18563	S-057	50% Dextrose Injection, USP
18561	S-057	70% Dextrose Injection, USP

These "Prior Approval" supplemental new drug applications update the prescribing information to reflect recommendations made in the October 8, 2015, Prior Approval Supplement Request letter regarding the conversion to Physician labeling Rule (PLR) format. Hospira participated in the Prescription Drug Labeling Improvement and Enhancement Initiative (PDLIEI).

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA

automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Heather Buck, Regulatory Project Manager, at (301) 796-1413.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
02/22/2016